Navigation Links
Organovo Reports Q3 2012 Financial Results, Provides Business Update
Date:11/16/2012

d expenses increased approximately of $97,500 over the same period in 2011, as a result of that move.

The approximate $42,278,500 increase in other income (expense) for the three month period ending September 30, 2012 over the same period of the prior year, was primarily related to the change in fair value of warrant liabilities for the three months ended September 30, 2012 of approximately $42,252,400.  During the Private Placement in the first quarter of 2012 we issued warrants to purchase 6,099,195 shares of our common stock to the placement agent and warrants to purchase 15,247,987 of our common stock to investors in the Private Placement. The warrants issued to the placement agent and Private Placement investors were determined to be derivative liabilities as a result of the anti-dilution provisions in the warrant agreements that may result in an adjustment to the warrant exercise price. We will revalue the derivative liability on each balance sheet date and will do so until the securities to which the derivatives liabilities relate are exercised or expire. The third quarter of 2012 also included a loss on disposal of fixed assets of approximately $158,400 which occurred in relation to moving to our new facility. Other expenses for the three months ended September 30, 2011 of approximately $182,800 related primarily to interest recorded on convertible notes payable.

About Organovo Holdings, Inc. Organovo is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. The Company's NovoGen three-dimensional bioprinting technology is a platform that works across all tissue and cell types. Organovo's NovoGen MMX Bioprinter was selected as one of the "Best Inventions of 2010" by TIME Magazine. Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic drug discovery and developm
'/>"/>

SOURCE Organovo Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
2. Organovo, Inc. to Webcast, Live, at RetailInvestorConferences.com on March 1st
3. Organovo, Inc. Investor Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
4. Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications
5. Organovo Announces Relocation and Commencement of Operations at Larger Facility
6. Organovo Holdings, Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
7. Organovo To Present At Lazard Healthcare Conference
8. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
9. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
10. Interleukin Genetics Reports Third Quarter 2011 Financial Results
11. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... OMICS Group International invites researchers, authors and academicians ... Access Week’ by actively contributing their research outcome ... from 20-26th October, 2014. , Pharmaceutical Sciences ... with a tremendous speed to provide improved medical ... is gearing with innovation and technological revolution to ...
(Date:9/18/2014)... and diabetes prevention, could actually hasten the development of ... in a surprising way: by changing the composition and ... of bacteria residing in our intestines. These findings, the ... today in Nature . Among other things, says ... who led this research together with Prof. Eran Segal ...
(Date:9/18/2014)... 18, 2014 Silicon-valley Electronic Data Capture ... Digitaliza TXT , the latest addition to Clinovo’s CRO ... Research Organization (CRO) Program, Clinovo further expands its global ... of ClinCapture training, we are now able to build ... Pulido. “We can also rely on Clinovo to fully ...
(Date:9/17/2014)... , Sept. 17, 2014  PDL BioPharma, Inc. (PDL) ... independent registered accounting firm, Ernst & Young LLP ("EY") that ... confirmed in a letter delivered to the Company on September ... September 16, 2014.  PDL has issued the ... have received a number of inquiries on the reason for ...
Breaking Biology Technology:Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 3PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3
(Date:9/17/2014)... a great deal about complex social behavior by studying ... to teach too. , With their unusually large brains ... live in a complex social environment---not merely in a ... ants, but in a dynamic setting of alliances and ... mammals: dolphins, whales, primates, and social carnivores, like hyenas ...
(Date:9/16/2014)... American Menopause Society (NAMS) has published its key, ... womenon everything from hot flashes to heart disease. ... Recommendations for Clinical Care of Midlife Women," was ... Menopause . This is the first, comprehensive set ... women freely available to all clinicians who care ...
(Date:9/16/2014)... that we inherit certain traits from our parents that ... these genes play out by taking certain drugs or ... what a team of researchers at the Boston University ... of epigenetics research. , Epigenetics regulates gene expression ... histone proteins, which prevent permanent mutations or alterations within ...
Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3
... 29, 2010) -- Wind turbines may be one of ... larger they also get noisier, become more of an ... solution: ocean-based wind turbines. While offshore turbines already have ... where the tower extends directly into the seabed. That ...
... -- The U.S. Supreme Court ruled 5-4 Monday that a ... the ability to patent software should not be limited. ... the "machine or transformation" test is not the sole test ... however, cannot be patented. IEEE-USA was party to an ...
... the Arctic climate system may be more sensitive to greenhouse ... atmospheric carbon dioxide may be high enough to bring about ... University of Colorado at Boulder, the international study indicated that ... High Arctic during the Pliocene Epoch 2.6 to 5.3 million ...
Cached Biology News:Arctic climate may be more sensitive to warming than thought, says new study 2Arctic climate may be more sensitive to warming than thought, says new study 3Arctic climate may be more sensitive to warming than thought, says new study 4
... all-inclusive collection of key procedures for use ... developed by the leaders in Pichia expression ... book will guide you from choosing the ... analysis, to production of your protein of ...
...
Antibodies were affinity purified using epitopes specific to USP33 immobilized on solid support....
... 30% of IgM-rheumatoid factor paraproteins ... not cross-react with IgM, IgA, or ... with pooled F(Ab)2 fragments. This antibody ... detect rheumatoid factor. Product Category: Hormone ...
Biology Products: